secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273250
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee Q3 net loss $65M; APG333 half-life ~55 days supports quarterly dosing; cash $913M, runway into 2H 2028
--------------------------------------------------------------------------------

- Q3 2025 net loss $65.0M vs $49.0M YoY; cash and securities $588.9M pre-offering, $913M pro forma post-$345M equity offering.
- APG333 Phase 1 data: half-life ~55 days, biomarker suppression for 6 months, well tolerated up to 1000 mg; supports quarterly or better dosing for APG273 co-formulation.
- APG777 readouts accelerated: Phase 1b asthma data Q1 2026; APEX Part A 52-week data Q1 2026; APEX Part B 16-week data Q2 2026; Phase 3 start 2H 2026.
- APG279 (APG777+APG990) head-to-head vs DUPIXENT in AD interim readout expected 2H 2026.
- Cash runway extended into 2H 2028 through Phase 3 topline data for APG777.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000119312525273250/0001193125-25-273250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000119312525273250/apge-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer